These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. Bai H; Mao L; Wang HS; Zhao J; Yang L; An TT; Wang X; Duan CJ; Wu NM; Guo ZQ; Liu YX; Liu HN; Wang YY; Wang J J Clin Oncol; 2009 Jun; 27(16):2653-9. PubMed ID: 19414683 [TBL] [Abstract][Full Text] [Related]
4. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Wu YL; Saijo N; Thongprasert S; Yang JC; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang JJ; Mok TS; Young H; Haddad V; Rukazenkov Y; Fukuoka M Lung Cancer; 2017 Feb; 104():119-125. PubMed ID: 28212993 [TBL] [Abstract][Full Text] [Related]
5. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455 [TBL] [Abstract][Full Text] [Related]
6. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054 [TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. Goto K; Ichinose Y; Ohe Y; Yamamoto N; Negoro S; Nishio K; Itoh Y; Jiang H; Duffield E; McCormack R; Saijo N; Mok T; Fukuoka M J Thorac Oncol; 2012 Jan; 7(1):115-21. PubMed ID: 21900837 [TBL] [Abstract][Full Text] [Related]
9. Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer. Ying H; Yang XD; Sun Z; Ning X; Wang Y; Bai C; Chen S; Wang Y Med Oncol; 2014 Oct; 31(10):220. PubMed ID: 25216867 [TBL] [Abstract][Full Text] [Related]
10. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876 [TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. Yoshida K; Yatabe Y; Park J; Ogawa S; Park JY; Shimizu J; Horio Y; Matsuo K; Mitsudomi T; Hida T J Cancer Res Clin Oncol; 2010 Apr; 136(4):527-35. PubMed ID: 19777258 [TBL] [Abstract][Full Text] [Related]
12. Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor. Sakai K; Horiike A; Irwin DL; Kudo K; Fujita Y; Tanimoto A; Sakatani T; Saito R; Kaburaki K; Yanagitani N; Ohyanagi F; Nishio M; Nishio K Cancer Sci; 2013 Sep; 104(9):1198-204. PubMed ID: 23721103 [TBL] [Abstract][Full Text] [Related]
14. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. Zhou Q; Zhang XC; Chen ZH; Yin XL; Yang JJ; Xu CR; Yan HH; Chen HJ; Su J; Zhong WZ; Yang XN; An SJ; Wang BC; Huang YS; Wang Z; Wu YL J Clin Oncol; 2011 Aug; 29(24):3316-21. PubMed ID: 21788562 [TBL] [Abstract][Full Text] [Related]
15. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212). Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334 [TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs). Martínez-Navarro EM; Rebollo J; González-Manzano R; Sureda M; Evgenyeva E; Valenzuela B; Fernández FJ; Forteza J; Brugarolas A Clin Transl Oncol; 2011 Nov; 13(11):812-8. PubMed ID: 22082647 [TBL] [Abstract][Full Text] [Related]
18. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS; N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359 [TBL] [Abstract][Full Text] [Related]
19. Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC. Behel V; Chougule A; Noronha V; Patil VM; Menon N; Singh A; Chopade S; Kumar R; Shah S; More S; Banavali SD; Chandrani P; Prabhash K Clin Lung Cancer; 2022 Jul; 23(5):410-418. PubMed ID: 35649817 [TBL] [Abstract][Full Text] [Related]
20. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L; Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]